Form 4: Supernus Pharmaceuticals CEO Settles Performance Share Units, Discloses Tax Withholding
SEC Form 4 Filing
CEO Jack A. Khattar settled performance share units and had shares withheld for tax obligations, according to a recent SEC filing.
Summary
- On March 7, 2025, Jack A. Khattar, CEO of Supernus Pharmaceuticals, settled 38,640 performance share units, receiving common stock.
- The company withheld 18,581 shares to satisfy tax withholding requirements related to the vesting of these units at a price of $39.11.
- Following these transactions, Khattar directly owns 973,638 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, common for publicly traded companies. It provides transparency into the holdings and transactions of company executives.
Stakeholder Impact
- The transaction affects the CEO's ownership stake in the company.
- The tax withholding impacts the company's financials.
Key Dates
| Date | Description |
|---|---|
| February 22, 2022 | Reporting Person was awarded Performance Share Units |
| May 3, 2022 | Objectives for Performance Share Units were established |
| March 7, 2025 | Settlement of Performance Share Units and tax withholding |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.